meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
new pathology
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus pomalidomide and dexamethasone
versus all
vs Immunosuppressant
vs pomalidomide based treatment
vs pomalidomide and dexamethasone
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
multiple myeloma - 2nd line (L2)
multiple myeloma - 2nd line (L2)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open